Read by QxMD icon Read

Recent Patents on Anti-infective Drug Discovery

Niccolò Riccardi, Marco Berruti, Filippo Del Puente, Lucia Taramasso, Antonio Di Biagio
BACKGROUND: Heavily treated HIV-1 infected patients may have limited therapeutic alternatives. In order to ensure sustained HIV-RNA suppression in these patients, new drugs are needed, to improve current antiretroviral treatment regimens in the fight against multi-drug resistant strains. Recently, two new drugs among the new generation of entry inhibitors showed promises for both their characteristics and mechanism of action. OBJECTIVE: To outline ibalizumab (Patent: US20120121597A1) and fostemsavir (Patent: US8871771) future applications in people living with multi-drug resistant HIV with few remaining treatment options...
October 31, 2018: Recent Patents on Anti-infective Drug Discovery
Da-Yong Lu, Ting-Ren Lu, Hong-Ying Wu, Nagendra S Yarla, Jian Ding, Bin Xu
BACKGROUND AND AIMS: AIDS (acquired immune deficient syndrome), a deadly human infectious disease is caused by HIV (human immunodeficiency viruses) infection. Patient's mortality was eventually reduced to one-fourth by combined chemotherapy (usually 3 chemical drugs simultaneously) than earlier HIV/AIDS treatments (single drug or vaccine) in the clinic. RESULTS: Combined treatments against HIV/AIDS are still incurable for all patients despite a high rate of patient's survival...
October 25, 2018: Recent Patents on Anti-infective Drug Discovery
Mehran Izadi, Banafsheh Dadsetan, Zeinab Najafi, Sirous Jafari, Elham Mazaheri, Omid Dadras, Hajar Heidari, SeyedAhmad SeyedAlinaghi, Fabricio Voltarelli
BACKGROUND: In Asia, an estimated of one million deaths caused by community-acquired pneumonia (CAP) each year. Despite the high mortality in elderly people, a large number of CAP patients have been treated and survived with optimal life expectancy. A few studies have been done on adult CAP therapeutic approaches in Asia. Moreover, differences have been noted between these studies and European data. We aimed to investigate the efficacy of oral Levofloxacin (TAVANEX), 750 mg, once daily for five days versus parenteral Ceftriaxone 1gr BD, plus oral Azithromycin (250 mg, once daily) for seven to ten days (standard regimen) in CAP treatment...
October 24, 2018: Recent Patents on Anti-infective Drug Discovery
Azar Shokri, Mahdi Fakhar, Saeed Emami, Pooria Gill, Javad Akhtari
AIM AND BACKGROUND: Azoles as antifungal drugs, has been used to treat leishmaniasis for many years. Several evidences suggesting that the primary target of azoles is the heme protein, which cocatalyzes cytochrome P-450-dependent 14α-demethylation of lanosterol. Little is known about the structural changes caused by azoles with atomic force microscopy (AFM) or scanning electron microscopy (SEM). In the current work several patented antileishmanial agents reviewed (US8809555) (US 0269803 A1) (TW201802093 A)...
September 18, 2018: Recent Patents on Anti-infective Drug Discovery
Shivani Verma, Puneet Utreja, Lalit Kumar
BACKGROUND: Acne is a multifactorial skin disease associated with pilosebaceous unit and caused by bacteria Propionibacterium acnes and Acne vulgaris. Near about 95% people throughout the world suffer from acne at some point in their life span. This disease is more prominent in adults compared to neonates and prepubescent children. Conventionally it is treated with either creams or gels having large number of side effects on patients. METHODS: We searched about recent advancements in the use of nanotechnological carriers for effective treatment of acne...
September 18, 2018: Recent Patents on Anti-infective Drug Discovery
Kanika Patel, Vikas Kumar, Amita Verma, Mahfoozur Rahman, Dinesh K Patel
There is the need of development of liposomes based nanomedicines formulation for the better efficacy and safety of the available drugs in the market. Liposomes have various applications in the field of pharmaceutical and medical field for their drug target potential, diagnostic importance and imaging techniques. Natural plant based drugs and their derivative have been used in the medicine, nutraceuticals, perfumery, cosmetic and beverages industry. More than half of the prescribed drugs in the worldwide are mainly derived from different natural sources...
September 13, 2018: Recent Patents on Anti-infective Drug Discovery
Sadaf J Gilani, Asadullah Jahangir, Chandra Kala, Mohammad Rizwanullah, Mohammad Taleuzzaman, Mohammad S Shahab, Kashif Shakil, Mohammad Aqil, Syed S Imam
BACKGROUND: According to the World Health Organization, skin cancer is the most common malignancy for the population. Conventional skin cancer treatment includes surgery and chemotherapy, but many of the chemotherapeutic agents used present undesirable properties. There are number of patents on topical nano formulation like nanoparticle (US9757453; US9457041), liposomes (US2018177726 (A1), has been covered in this review in the treatment of skin cancer. METHODS: Encapsulated drugs are advantageous due to such properties as high stability, better bioavailability, controlled drug release, a long blood circulation time, selective organ or tissue distribution, a lower total required dose, and minimal toxic side effects...
September 10, 2018: Recent Patents on Anti-infective Drug Discovery
Mehdi R Rad, Hossein Kazemian, Fateme Yazdani, Mohamad R Z Monfared, Hoseinali Rahdar, Ali Javadi, Mansoor Kodori
BACKGROUND AND OBJECTIVE: Today, resistance to multiple classes of antibiotics, and notably to the β-lactam and aminoglycosides in A. baumannii is becoming great problem and it's necessitate to make new approach to combat with multidrug-resistant (MDR), extensive drug-resistance (XDR) or Pandrug-resistant (PDR) isolates. In this case new strategy and ways should be designed and introduce against such infections. Therefore the aim of present study was evaluation of antibacterial activity of nanoconjugate gentamicin and amikacin with gold against clinical isolates of A...
August 27, 2018: Recent Patents on Anti-infective Drug Discovery
Manzar Alam, Mohd Imran
BACKGROUND: Hospital wastewater has a high amount of both organic and inorganic matter, as well as high densities of living organisms, including pathogenic, and environmental bacteria. It has been suggested that genes encoding resistance to antibiotic can be located together with heavy metals resistance genes on either the same genetic structure (plasmid), or different genetic structures within the same bacterial strain. Resistance transfer is mainly attributed to conjugation since many antimicrobial resistance genes are situated on mobile elements, such as plasmids and conjugative transposons, whereas renovation and transduction are usually more limited...
July 1, 2018: Recent Patents on Anti-infective Drug Discovery
Komal Sharma, Shams Aaghaz, Kitika Shenmar, Rahul Jain
BACKGROUND: After the era of serendipitous discovery of penicillin and outburst in the discovery and development of highly efficient antibiotics, a surge in resistance against the target specific drugs was observed, primarily due to a combination of selective pressure of antibiotics use and spontaneous mutations. As per the World Health Organization, antibiotic resistance is one of the greatest threats to the mankind. OBJECTIVE: Short antimicrobial peptides (SAMPs) can be considered as a viable therapeutic alternative to conventional antibiotics in tackling resistant microbes...
June 27, 2018: Recent Patents on Anti-infective Drug Discovery
Hossein Kazemian, Hamid Heidari, Jalil Kardan Yamchi, Hengameh Zandi, Asieh Taji, Fateme Yazdani, Roya Ghanavati, Hossein Ali Rahdar, Mohammad Mehdi Feizabadi
BACKGROUND: Mycobacterium tuberculosis as an intracellular pathogen causes tuberculosis (TB). Due to the long time required for treatment, hepatotoxicity of drugs and also emergence of multidrug-resistant (MDR) and extremely drug resistant (XDR) strains, TB is currently a major public health problem. Some medicinal plants possess remarkable activity against Mycobacterium. Among them, Lamiaceae family are of pharmaceutical interest because of their potential antimicrobial properties. The aim of the study was to evaluate the in vitro activities of Satureja rechingeri, Satureja khuzestanica and Zataria multiflora against MDR M...
June 26, 2018: Recent Patents on Anti-infective Drug Discovery
Kanika Thakur, Gajanand Sharma, Bhupinder Singh, Sanjay Chhibber, Om Prakash Katare
BACKGROUND: Topical infections, involving a number of diseases such as impetigo, eczema, pustular acne, psoriasis and infected seborrheic dermatitis are one among the many challenges to health which stand out for their profound impact on human species. The treatment of topical infections has always been a difficult proposition because of the lack of efficacy of existing anti-infectives, longer period of treatment and yet incomplete recovery. The increasing emergence of antibiotic resistant bacterial strains like Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa undermine the need of development of new delivery systems to enhance the therapeutic efficacy of existing topical anti-infectives...
May 28, 2018: Recent Patents on Anti-infective Drug Discovery
Roya Ghanavati, Elnaz Ohadi, Hossein Kazemian, Fateme Yazdani, Alireza Torki, Behrooz S. Kalani, Gholamreza Irajian
BACKGROUND: Rising rates of antimicrobial resistance among Enterobacteriaceae limit the use of reliably active forms of available drugs. The aim of this study was to investigate the prevalence of fosfomycin (US6794490B2) resistance gene among ESBL producing isolates in Iran. METHOD: We tested 355 isolates of Enterobacteriacea collected from various clinical samples including urine, wounds, blood and other sources during June 2016 to July 2017. Antibiotic sensitivity and extended spectrum beta lactamase (ESBL) production were tested using agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines...
May 16, 2018: Recent Patents on Anti-infective Drug Discovery
Fereshteh Satarian, Hamideh Mahmoodzadeh Hosseini, Abdolamir Ghadaksaz, Mohsen Amin, Abbas Ali Imani Fooladi
BACKGROUND: Multi-drug resistance among Pseudomonas aeruginosa (P. aeruginosa) clinical isolates is increasing and becoming a serious problem for public health authorities worldwide. OBJECTIVE: The aim of current study is the introducing a potent antibacterial compound against the resistant P. aeruginosa. The recent patents on antimicrobial properties of extracts drived from Apiaceae family plants (WO2017216602A1, KR20050054247A and KR100285781B1) were used to to assess other member Ferula gummosa (F...
April 26, 2018: Recent Patents on Anti-infective Drug Discovery
(no author information available yet)
No abstract text is available yet for this article.
2018: Recent Patents on Anti-infective Drug Discovery
Dieter Kabelitz
No abstract text is available yet for this article.
2018: Recent Patents on Anti-infective Drug Discovery
Imran Ahmed, Yanyan Fang, Min Lu, Quan Yan, Ahmed El-Hussein, Michael R Hamblin, Tianhong Dai
BACKGROUND: Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based anti-infective therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains...
2018: Recent Patents on Anti-infective Drug Discovery
Abul Barkat, Harshita, Sarwar Beg, Javed Naim, Faheem H. Pottoo, Satya P. Singh, Farhan J. Ahmad
Background: Silver nanoparticles (AgNPs), are amongst the utmost striking na-nosized materials that are extensively applied in a variety of biomedical applications which includes diagnostic use, disease management, medical device coating, drug delivery and for personal health care. Discussion: With the growing interest and its application in the health care sector, it is be-coming necessary for a better understanding and exploration of AgNPs mechanism of ac-tion like biological interaction, their possible toxicity, and safety concern to human expo-sure...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
Hossein Kazemian, Samane Bourbour, Maryam Beheshti, Abbas Bahador
BACKGROUND: Critically ill patients are very susceptible to a variety of disorders and infections during hospitalization in Intensive Care Units [ICU]. Among these problems, nosocomial infections are major causes of morbidity and mortality. METHODS: Nosocomial pneumonias, specifically ventilator associated pneumonias have become a major health care issue. The implication of oral care in hospital presents challenges that can prevent or reduce the risk of nosocomial pneumonias in ICU...
October 2, 2017: Recent Patents on Anti-infective Drug Discovery
Niccolò Riccardi, Filippo Del Puente, Federica Magnè, Lucia Taramasso, Antonio Di Biagio
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); moreover, 680,000 people developed multidrug-resistant TB (MDR-TB). Methods: Currently available anti-MDR and XDR regimens are long-lasting and expensive, need high adherence and are undermined by a high frequency of adverse drug events, thus leading to a low success rate; moreover, in the last 50 years only two new molecules, bedaquiline (BDQ) and delamanid, have been approved and released for treatment of MDR-TB...
June 19, 2017: Recent Patents on Anti-infective Drug Discovery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"